Fresenius Medical Care AG
Fresenius Medical Care is a medical technology and healthcare services company serving people with kidney disease. Its Care Delivery segment operates a global network of dialysis clinics and provides in-center and home dialysis, hospital dialysis services, and related care, including vascular services, laboratory testing, pharmacy services and support for nephrologists. Value-Based Care, operated through Interwell Health, uses risk-based care models and works with nephrologists and clinical practices in the U.S. Care Enablement develops, manufactures and distributes kidney-care devices, systems, products and pharmaceuticals, including hemodialysis and peritoneal dialysis equipment, dialyzers, dialysis solutions and acute-care products. Fresenius Medical Care earns money by providing healthcare services and selling medical products and pharmaceuticals. It serves customers in more than 140 countries and operates 3,601 dialysis centers as of December 31, 2025. The company’s principal office is in Bad Homburg, Germany.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $FMS in the last 30 days.
See all $FMS insider activity →Fresenius stock rose 1.8% to €48.675 after announcing an exclusive deal with WuXi Biologics for up to 37 biosimilar candidates. The company aims to triple its portfolio and maintained its 2026 and 2030 guidance. JPMorgan kept its Overweight rating with a €55.20 price target.
HHS Secretary Robert F. Kennedy Jr. announced a plan to reduce regulatory barriers in kidney care, aiming to increase competition and patient choice. The plan targets dialysis market dominance by DaVita and Fresenius Medical Care, which control 74% of the market, and proposes simplifying certification requirements. It also seeks to streamline kidney transplant processes and reduce financial barriers for living donors, but stops short of allowing direct compensation for organs.
Fresenius SE & Co. KGaA (FRE GR) and its affiliates faced 65 FOIA requests in 2026, seeking FDA inspection reports on its U.S., German, and Colombian plants. Requests came from law, financial, and research firms, signaling potential regulatory scrutiny. Fresenius operates global healthcare businesses, including drug manufacturing and hospital services.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning FMS (Fresenius Medical Care AG). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent FMS coverage spans financial news, regulation and technology.
The deal expands Fresenius' biosimilar pipeline and is likely to lift the stock.
Potential pressure on Fresenius Medical Care as reforms could increase competition.
Similar regulatory focus on its manufacturing sites could affect earnings outlook.
The new system may boost Fresenius' revenue from continuous kidney replacement therapy and improve market share.
Potential share decline due to anticipated competitive pressures.
AlphAI scores every news story that mentions FMS with an AI model for sentiment and relevance, and aggregates insider trades from Fresenius Medical Care AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
Fresenius stock rose 1.8% to €48.675 after announcing an exclusive deal with WuXi Biologics for up to 37 biosimilar candidates. The company aims to triple its portfolio and maintained its 2026 and 2030 guidance. JPMorgan kept its Overweight rating with a €55.20 price target.
2 min readHHS Secretary Robert F. Kennedy Jr. announced a plan to reduce regulatory barriers in kidney care, aiming to increase competition and patient choice. The plan targets dialysis market dominance by DaVita and Fresenius Medical Care, which control 74% of the market, and proposes simplifying certification requirements. It also seeks to streamline kidney transplant processes and reduce financial barriers for living donors, but stops short of allowing direct compensation for organs.
2 min readFresenius SE & Co. KGaA (FRE GR) and its affiliates faced 65 FOIA requests in 2026, seeking FDA inspection reports on its U.S., German, and Colombian plants. Requests came from law, financial, and research firms, signaling potential regulatory scrutiny. Fresenius operates global healthcare businesses, including drug manufacturing and hospital services.
3 min readFresenius Medical Care received FDA clearance for its multiFiltratePRO ICU kidney system, which integrates citrate and calcium pumps for continuous kidney replacement therapy. The system aims to simplify treatment for acute kidney injury patients. The company plans to showcase the product at ASN Kidney Week 2026.
2 min readDaVita (DVA) and Fresenius Medical Care (FMS) shares fell on Tuesday after Axios reported the Trump administration plans to promote competition in the dialysis market. The move aims to reform the industry, potentially impacting the two leading providers.
1 min readFresenius Medical Care presented studies at Kidney Week 2026, including findings that GLP-1 receptor agonists were linked to lower mortality and fewer hospitalizations in about 5,000 dialysis patients. The company also shared data on high-volume hemodiafiltration (HvHDF) and AI-based clinical insights. Fresenius Medical Care is listed on the Frankfurt (FME) and New York (FMS) stock exchanges.
2 min readFresenius Medical Care, a leader in dialysis services, expects low-to-mid single-digit revenue growth over the next five years. The company plans to resume margin expansion after a 2026 pause, aiming to boost profits. Demand is expected to remain strong in developed and emerging markets, despite long-term obesity drug threats.
2 min readFresenius Medical Care ADR (FMS) shares fell 6.9% to $20.87 after announcing CEO Helen Giza's abrupt departure and Shervin J. Korangy's appointment. Analysts recently cut price targets, and Q3 earnings are due in November. Broader market declines and rising oil prices added pressure, pushing FMS near its 52-week low.
1 min readFresenius Medical Care (FME) announced Shervin J. Korangy as its new CEO, effective October 12, 2026. He succeeds Helen Giza, who led the company's transformation and cost reduction by EUR 1.2 billion. Korangy, a healthcare executive, will focus on growth, innovation, and market leadership. FME is a global provider of renal disease products and services, listed on the Frankfurt and NYSE.
2 min readGE HealthCare appointed Rodolphe Katra as Global Chief AI Officer, expanding AI use in medical devices. Danaher announced Shashanka Muppaneni as Chief Strategy Officer. Enhertu, developed by AstraZeneca and Daiichi Sankyo, received EU and UK recommendations for breast cancer treatment. Fresenius Medical Care and NHS are building the UK's first net-zero dialysis center.
2 min read
